Literature DB >> 17200765

Rapid activation of haemostasis after hormonal emergency contraception.

Marianne van Rooijen1, Angela Silveira, Stella Thomassen, Lars-Olof Hansson, Jan Rosing, Anders Hamsten, Katarina Bremme.   

Abstract

Hormonal emergency contraception (EC) is a well established contraceptive method, recommended to all women, although the effects on haemostais are not fully evaluated. The aim of this study was to evaluate whether exposure to EC has effects on well established cardiovascular risk factors, and also to examine whether differences exist between two EC treatments. In a prospective randomized cross over design 11 women used two different EC methods, one with estrogen and levonorgestrel (EE-EC) and one with levonorgestrel only (LNG-EC). Plasma concentrations of haemostatic factors (APC resistance, antithrombin, fibrinogen, prothrombin fragment 1 + 2, free protein S, factorVII and PAI-1), sex-hormone-binding globulin (SHBG), the apolipoprotein (apo)B/apoA1 ratio and C-reactive protein (CRP) were followed frequently during the following 48 hours. A rapid haemostatic activation was induced with both treatments, although more pronounced with EE-EC. Already two hours after EC, the plasma concentrations of haemostatic parameters and SHBG were significantly different from baseline concentrations. An ETP-based APC-resistance method showed increased APC resistance with EE-EC and decreased APC resistance with LNG-EC. The ApoB/ApoA1 ratio was affected in a favourable direction with EE-EC.CRP increased slightly regardless of treatment. Even a very short exposure to exogenous sex hormones causes prompt effects on hepatic protein synthesis and the coagulation system. This must be taken into consideration whenever exogenous steroid hormones are administered, especially to individuals with a genetic predisposition to thrombosis or transiently disturbed haemostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200765

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Endogenous thrombin potential changes during the first cycle of oral contraceptive use.

Authors:  Carolyn L Westhoff; Malcolm C Pike; Serge Cremers; Andrew Eisenberger; Stella Thomassen; Jan Rosing
Journal:  Contraception       Date:  2017-01-11       Impact factor: 3.375

Review 2.  A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.

Authors:  Nattawut Leelakanok; Janthima Methaneethorn
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

3.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Exposure to particulate air pollution and risk of deep vein thrombosis.

Authors:  Andrea Baccarelli; Ida Martinelli; Antonella Zanobetti; Paolo Grillo; Li-Fang Hou; Pier A Bertazzi; Pier Mannuccio Mannucci; Joel Schwartz
Journal:  Arch Intern Med       Date:  2008-05-12

5.  Intraoperative blood loss in female patients with adolescent idiopathic scoliosis during different phases of the menstrual cycle.

Authors:  Chao Li; Yang Xie; Zhikun Li; Mingyuan Yang; Xiaofei Sun; Jianping Fan; Honglei Yi Xiaodong Zhu; Chuanfeng Wang; Ming Li
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

6.  Preoperative factors predicting intraoperative blood loss in female patients with adolescent idiopathic scoliosis.

Authors:  Chao Li; Mingyuan Yang; Chao Wang; Chuanfeng Wang; Jianping Fan; Ziqiang Chen; Xianzhao Wei; Guoyou Zhang; Yushu Bai; Xiaodong Zhu; Yang Xie; Ming Li
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

7.  Gender differences in response to chronic treatment with 17β-oestradiol and 17β-aminoestrogen pentolame on hemostasis in rats.

Authors:  Cristina Lemini; Ruth Jaimez; Martha Medina-Jiménez; María Estela Ávila
Journal:  Indian J Pharmacol       Date:  2012 Nov-Dec       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.